Kardigan, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Kardigan, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $806.00K, a 571.67% increase year-over-year.
- Kardigan, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $427.00K.
- Kardigan, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $120.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $806.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $427.00K 10-Q · filed 2026-08-11 | |
| 2025-06-30 | $120.00K 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |